Smith & Nephew PLC

Smith & Nephew reported second-quarter GAAP earnings per share of $0.36 on revenue of $1.6 billion, up 3.2% year-over-year. Trading profit for the first half reached $566 million, an 8.10% increase year-over-year, expanding the trading profit margin by 60 basis points to 18.30%. Cash generated from operations reached $605 million.

Smith+Nephew has received De Novo classification from the U.S. Food and Drug Administration for its TESSA Spatial Surgery System, a first-of-its-kind device in a new FDA category for intra-articular orthopedic stereotaxic navigation instruments. The system uses preoperative MR or CT scans with cloud-based deep-learning algorithms on Amazon Web Services and NVIDIA AI infrastructure to generate patient-specific 3D anatomical models, overlaying them onto live 4K arthroscopic video for real-time navigation. Its first indication is femoral anterior cruciate ligament reconstruction surgery of the knee, where femoral malposition at 29% and tibial malposition at 11% are among the most common reasons for ACLR failure. The TESSA System will be commercially introduced during Q3 2026 with increased deployment in 2027. The technology was originally developed by Perceive3D S.A., a University of Coimbra spin-off acquired by Smith+Nephew.

Smith+Nephew has unveiled an expanded ASC Solutions strategy aimed at helping ambulatory surgery centers improve operational efficiency and deliver better patient outcomes. The enhanced enterprise approach combines the company's procedural technologies, data-driven insights, and a strategic partner network that includes STERIS, Unity Health Centers, Brasfield & Gorrie, Ghafari, and Hopper Healthcare. A key component is the broader rollout of the ASC ONE delivery model, an integrated platform that provides coordinated support across development planning, facility design, financing, and clinical enablement. The move targets the fast-growing outpatient care market, which Grand View Research projects will grow from $160.7 billion in 2026 to $205.5 billion by 2030. Smith+Nephew currently has a market capitalization of $12.76 billion.

The global surgical robots market is projected to grow from USD 13.69 billion in 2025 to USD 27.14 billion by 2030, at a compound annual growth rate of 14.7%, according to a new report by MarketsandMarkets. Growth is driven by increasing demand for minimally invasive surgeries, rising surgical volumes linked to chronic diseases and an aging population, and advances in robotic platforms, 3D visualization, AI-assisted navigation, and surgical instrumentation. Instruments and accessories represent the largest offering segment, general surgery is the largest application segment, and hospitals and clinics are the largest end-user segment. Asia Pacific is expected to be the fastest-growing regional market, with key players including Intuitive Surgical, Stryker Corporation, Medtronic, Smith+Nephew, and Zimmer Biomet.

The global biomaterial wound dressing market is projected to grow from $6.18 billion in 2025 to $8.62 billion by 2030, according to a new report from ResearchAndMarkets.com. The market is expected to reach $6.65 billion in 2026, reflecting a compound annual growth rate of 7.6% from 2025. Growth is driven by an increase in surgical procedures, rising chronic wounds, and adoption of advanced dressing technologies. North America was the largest market in 2025, while Asia-Pacific is expected to lead future growth. Key players include Johnson & Johnson, The 3M Company, Medline Industries, and Smith & Nephew.

A new interdisciplinary expert consensus published in Die Chirurgie provides the first risk-based recommendations in Germany for the use of single-use negative pressure wound therapy in closed surgical incisions. The guidance, developed independently by clinicians and supported by Smith+Nephew, identifies sNPWT as a targeted preventive option for patients at increased risk of postoperative wound complications, including those with obesity, diabetes mellitus, smoking, or procedure-related factors such as prolonged surgical duration or revision surgery. It recommends sNPWT for wounds with an anticipated exudate volume of up to 300 ml per week and highlights the importance of structured preventative strategies to reduce complications like prolonged wound drainage and seroma formation. The consensus also references the PICO 7 sNPWT system, noting its canister-free, portable design and features such as a dressing change indicator and visual leak detection that support integration into clinical pathways.